BridgeMD
New treatment option for Carpal Tunnel Syndrome (CTS)
Official title Effects of Kaltenborn and Mulligan Mobilisation in Patients With Carpal Tunnel Syndrome.
ClinicalTrials.gov ID: NCT06687018
What this study is testing
- What it's testing
- Carpal Tunnel Syndrome is the most common mononeuropathy that results from the compression of median nerve in carpal tunnel, leading to entrapment neuropathy. The symptoms become aggravated during drawing, typing or playing video games.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 45
You may be able to join if
- Both genders between 20 and 45 years of age
- Individuals having localized pain, tingling and numbness in the median nerve distribution
- Positive Tinel sign and positive Phalen's test
You likely can't join if
- Any sensory and/or motor deficit in either the ulnar or radial nerve traumatic neck injury
- Previous hand surgery or trauma or cervical radiculopathy
- Systemic disease e.g. diabetes mellitus or thyroid disease or rheumatoid arthritis
The study team makes the final eligibility decision.
Where it's taking place
- Lahore, Punjab Province, Pakistan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years to 45 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lahore, Punjab Province, Pakistan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.